Press release
Exosomes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Discover the latest drugs and treatment options in the Exosomes Pipeline. Dive into DelveInsight's comprehensive report today! @ Exosomes Pipeline Outlook [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Exosomes Pipeline Report
* In August 2024:- Ablon Skin Institute Research Center- The goal of this clinical trial is to further substantiate the effectiveness and safety of BENEV Exosome Regenerative Complex+ post SylFirmX Registered RF microneedling procedure for self-perceived thinning hair in healthy men and women ages 18-65 over the course of four months. Participants will be asked to have treatments monthly for 4 sessions, attend a follow up appointment 4 weeks after the 4th session, have photos taken of their hair and answer questionnaires related to their thinning hair.
* DelveInsight's Exosomes pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Exosomes treatment.
* The leading Exosomes Companies such as Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, and Direct Biologics, and others.
* Promsiing Exosomes therapies such as Anlotinib, AGLE 102, TISSEEL, and others.
Stay ahead with the most recent pipeline outlook for Exosomes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Exosomes Treatment Drugs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Exosomes Emerging Drugs
* CAP-1002: Capricor
Capricor's (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor's scientific founder, Dr. Eduardo Marban. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. CAP-1002 contains cardiosphere-derived cells, a type of heart cell progenitor, or precursor cell, that secretes tiny vesicles called exosomes. These exosomes then modulate the activity of the immune system and stimulate cellular regeneration. It is being investigated for its potential to modify the immune system's activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. Currently, the drug is in Phase III stage of its development for the treatment of Duchenne Muscular Dystrophy.
* Progenza: Regeneus
Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing. Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types. The MSCs are expanded through the company's proprietary and scalable manufacturing process. The company has demonstrated the capacity to produce millions of therapeutic doses of Progenza from a single donor. When Progenza cells are injected into the damaged joint or tissue, the MSCs have the potential to reduce pain and inflammation and slow the progression of disease. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Osteoarthritis.
* AGLE 102: Aegle Therapeutics
AGLE-102 contains COL7 protein as well as COL7A1 mRNA, which in preclinical models stimulates recessive DEB cells (cannot make any COL7) to produce COL7. AGLE-102 has the potential to induce functional regeneration and organization of complex tissue structures in DEB and EB patients that can potentially accelerate and enhance healing, reduce scarring, and improve overall cosmesis. In addition, AGLE-102 is non-immunogenic and carries the immunomodulating and anti-inflammatory properties of MSCs. Aegle's Phase I/II clinical trial involving AGLE-102 in individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) is now open for enrollment. Currently, the drug is in Phase I/II stage of its development for the treatment of Dystrophic Epidermolysis Bullosa.
Explore groundbreaking therapies and clinical trials in the Exosomes Pipeline. Access DelveInsight's detailed report now! @ New Exosomes Drugs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Exosomes Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Exosomes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Exosomes Market Drivers and Barriers [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Exosomes Pipeline Report
* Coverage- Global
* Exosomes Companies- Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, and Direct Biologics, and others.
* Exosomes therapies- Anlotinib, AGLE 102, TISSEEL, and others.
* Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Exosomes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Exosomes Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Exosomes : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Exosomes - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CAP-1002: Capricor Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Progenza: Regeneus
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* AGLE 102: Aegle Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Exosomes Key Companies
* Exosomes Key Products
* Exosomes - Unmet Needs
* Exosomes - Market Drivers and Barriers
* Exosomes - Future Perspectives and Conclusion
* Exosomes Analyst Views
* Exosomes Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=exosomes-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exosomes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3692176 • Views: …
More Releases from ABNewswire
Flexdolly Redefines Moving Services San Diego Industry Standards with Transparen …
Flexdolly Moving & Delivery - San Diego establishes transparent pricing standards, eliminating hidden fees in relocation services, driving 77.8% client retention through honest cost communication and detailed estimates.
Moving services San Diego [https://www.google.com/search?&oq=moving+services+san+diego&kgmid=/g/11q95v7ybh] providers face increasing scrutiny over hidden fees and unclear pricing structures, prompting Flexdolly Moving & Delivery - San Diego to establish a new standard for upfront cost transparency among San Diego moving companies. The veteran-owned business has implemented…
Oxygenation Therapy Center Reports Improved Patient Outcomes in Joint Inflammati …
Los Angeles wellness center Ebo2 Therapy and Wellness documents improved patient outcomes in joint inflammation cases using specialized blood oxygenation protocols, with patients reporting reduced discomfort and enhanced mobility.
EBOO treatment [https://www.google.com/search?&oq=eboo+treatment&kgmid=/g/11x0cp3yz5] has emerged as a promising approach for managing joint inflammation, according to recent patient outcomes documented by a Los Angeles-based wellness center. Ebo2 Therapy and Wellness has reported consistent positive results among individuals seeking relief from chronic joint discomfort,…
Las Vegas Hospice Care Provider Expands Family Grief Support Services Throughout …
Summerlin Hospice and Palliative Care expands grief support services across Nevada, offering enhanced counseling, bereavement resources, and specialized programs for families experiencing loss and serious illness.
Las vegas hospice care [https://www.google.com/maps/place/las+vegas+hospice+care/@36.0561135,-115.0880966,129624m/data=!3m2!1e3!4b1!4m6!3m5!1s0x80c8eb1818c4d49f:0xc093154d4fd27666!8m2!3d36.0561135!4d-115.0880966!16s%2Fg%2F11w3v1q2cj!5m1!1e1?entry=ttu&g_ep=EgoyMDI1MTIwMi4wIKXMDSoASAFQAw%3D%3D] families now have access to expanded grief support services as Summerlin Hospice and Palliative Care announces a significant enhancement of emotional and spiritual resources across Nevada. The family-owned provider, based at 2620 Regatta Drive in Las Vegas, now offers enhanced…
Swamp Rabbit Moving Emerges as Leading Long Distance Movers Greenville with Expa …
Swamp Rabbit Moving expands service capabilities in Greenville with enhanced interstate solutions, a dedicated fleet, climate-controlled storage, and specialized moving options for residential and commercial clients throughout South Carolina's Upstate region.
Long-distance movers Greenville [https://www.google.com/search?&oq=long+distance+movers+greenville&kgmid=/g/11xs89zh2x] residents and businesses rely on to continue to raise service standards as Swamp Rabbit Moving reinforces its commitment to providing comprehensive relocation solutions. The Simpsonville-based company has established itself as a reliable option throughout the Greenville…
More Releases for Exosome
Spotlight on Exosome Delivery Technology - Creative Biolabs Showcased at the 202 …
On September 25, 2025, the multi-day 7th Exosome-Based Therapeutic Development Summit concluded successfully.
New York, USA - October 13, 2025 - During the presentations and panel discussions, participants noted the special benefits exosomes bring-including excellent biocompatibility, low immunogenicity, and the ability to cross biological barriers-reiterating their great promise in cancer treatment, neurological disorders, and immune regulation. When compared with liposomes and traditional nanoparticles, exosomes offer greater efficiencies in carrying nucleic acids,…
Emerging Trends to Reshape the Exosome Technologies Market: Creative Biolabs Lau …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Exosome Technologies Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the exosome technologies market size has seen a significant exponential growth. The market is projected to expand from $0.07 billion in 2024 to $0.09 billion in 2025, with a compound…
Exosome Therapy Market May See a Big Move | Major Giants- Exiqon, Exosome Diagno …
HTF MI recently introduced Global Exosome Therapy Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborating market size (2024-2031). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence.
The Major Players Covered in this Report: Sistemic Ltd Aethlon Medical, Inc. (United States), Exosome Diagnostic, Inc. (United States), Thermo Fisher Scientific, Inc. (United…
Exosome Innovations Transforming Healthcare Solutions
The global exosome diagnostic and therapeutic market is witnessing remarkable growth, with its projected value reaching an astounding USD 22,609.77 million by 2034, up from USD 33.04 million in 2023. This meteoric rise represents a staggering compound annual growth rate (CAGR) of 81.03% from 2024 to 2034. As the market continues to expand, the spotlight is firmly on exosomes, small extracellular vesicles that play a significant role in a variety…
Exosome Technologies Market Report 2024 - Exosome Technologies Market Size, Shar …
"The Business Research Company recently released a comprehensive report on the Global Exosome Technologies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The exosome technologies market size…
Exosome technologies Market Growth Expected to See Next Level | Exosome Diagnost …
The Latest Study Published by HTF MI Research on the "Exosome technologies Market'' evaluates market size, trend and forecast to 2030. The Exosome technologies market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges as well…
